Drug Discovery and Development for Neglected Tropical Diseases

EasyChair Preprint 15049

Abstract

Neglected Tropical Diseases (NTDs) encompass a group of infectious diseases that disproportionately affect impoverished populations in tropical and subtropical regions. Despite their significant burden on public health, NTDs have historically received limited attention from the pharmaceutical industry, leaving a critical gap in drug discovery and development. This review highlights the challenges and advancements in the field of drug development for NTDs, focusing on diseases such as leishmaniasis, Chagas disease, and schistosomiasis. Traditional approaches have relied heavily on repurposing existing drugs, but recent breakthroughs in genomic and molecular biology have opened new avenues for targeted drug design. Public-private partnerships, open-source drug discovery platforms, and global initiatives have also played a crucial role in accelerating the development of novel therapeutics. However, substantial barriers remain, including limited funding, inadequate infrastructure in affected regions, and the need for innovative delivery mechanisms to ensure access to life-saving treatments. Addressing these challenges is imperative to reducing the global burden of NTDs and improving health outcomes in vulnerable populations. This abstract calls for continued collaboration and investment in the discovery and development of effective, affordable, and accessible treatments for NTDs.

Keyphrases: BET, Bromodomain, Epigenetics, cancer, dual inhibitor, inhibitor, kinase

@booklet{EasyChair:15049,
  author    = {Favour Olaoye and Kaledio Potter and Axel Egon},
  title     = {Drug Discovery and Development for Neglected Tropical Diseases},
  howpublished = {EasyChair Preprint 15049},
  year      = {EasyChair, 2024}}